Kazam Joshua A 4
4 · Allogene Therapeutics, Inc. · Filed Dec 22, 2025
Insider Transaction Report
Form 4
Kazam Joshua A
Director
Transactions
- Exercise/Conversion
Common Stock
2025-12-18+47,700→ 350,763 total - Exercise/Conversion
Restricted Stock Unit
2025-12-18−47,700→ 47,700 total→ Common Stock (47,700 underlying)
Footnotes (3)
- [F1]On June 23, 2025, this grant was erroneously reported as 94,500 shares and is corrected here upon the vesting of the first of the semi-annual installments.
- [F2]Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2018 Plan.
- [F3]Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date.